Phase 1a, First-In-Human, Dose-Escalation Study of (+)-SJ000557733 (SJ733), an Oral, Novel Inhibitor of Plasmodium Falciparum Plasma Membrane Protein PfATP4
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
At a glance
- Drugs SJ 733
- Indications Malaria
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms BUZZOFF
- 15 Feb 2018 Last checked against ClinicalTrials.gov record.
- 12 Feb 2018 Planned number of patients changed from 40 to 50.
- 09 Nov 2017 Planned End Date changed from 31 Dec 2017 to 1 Jul 2018.